STOCK TITAN

Redwood Scientific Technologies Inc. (RSCI. OTC. PK) Issues Correction Regarding Agreement with Silk Road Ent., Inc.

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Redwood Scientific Technologies Inc. corrects a previous press release, clarifying that the arrangement with Silk Road Ent., Inc. was a 'Marketing Consulting Agreement' and not a partnership. Redwood has canceled the agreement and prohibited Silk Road from marketing or selling its premarket development products. CEO Jason Cardiff expresses confidence in regulatory compliance and establishing beneficial partnerships.
Positive
  • None.
Negative
  • None.

NEW YORK, Aug. 15, 2023 /PRNewswire/ -- Redwood Scientific Technologies Inc. wishes to correct a previous press release issued on July 19th. Contrary to the previous statement, the arrangement between Redwood Scientific Technologies Inc. and Silk Road Ent., Inc. was not a partnership agreement. Rather, it was accurately termed a "Marketing Consulting Agreement."

Effective immediately, Redwood Scientific Technologies Inc. has formally notified Silk Road Ent., Inc. of the cancellation of the aforementioned "agreement." Furthermore, Silk Road Ent., Inc. has been informed that they are and have been prohibited from engaging in any marketing, promotion, or sale of Redwood Scientific Technologies Inc.'s products that are currently in the premarket development stage.

Jason Cardiff, CEO of Redwood Scientific Technologies Inc., commented on the cancellation, stating, "Redwood maintains its unwavering confidence in its ability to adhere to all regulatory requirements set forth by relevant agencies in the process of bringing our products to market. This includes ensuring the establishment of the most advantageous partnerships for the benefit of our valued shareholders."

For further information, please contact:
Email: Info@redwoodsci.co
Phone: 646-503-7884

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/redwood-scientific-technologies-inc-rsci-otc-pk-issues-correction-regarding-agreement-with-silk-road-ent-inc-301900750.html

SOURCE Redwood Scientific Technologies Inc.

FAQ

What is the correction made by Redwood Scientific Technologies Inc.?

Redwood clarified that the arrangement with Silk Road Ent., Inc. was a 'Marketing Consulting Agreement' and not a partnership.

What actions has Redwood taken regarding the agreement with Silk Road?

Redwood has canceled the agreement and prohibited Silk Road from marketing, promoting, or selling its premarket development products.

Who commented on the cancellation?

CEO Jason Cardiff of Redwood Scientific Technologies Inc. commented on the cancellation.

What is the CEO's statement regarding regulatory requirements and partnerships?

Jason Cardiff expressed confidence in adhering to regulatory requirements and establishing advantageous partnerships for the benefit of shareholders.

How can I contact Redwood Scientific Technologies Inc. for further information?

You can contact Redwood via email at Info@redwoodsci.co or by phone at 646-503-7884.

Redwood Scientific Technologies, Inc.

OTC:RSCI

RSCI Rankings

RSCI Latest News

RSCI Stock Data

148.68M
All Other Miscellaneous Chemical Product and Preparation Manufacturing
Manufacturing
Link
United States of America
Claremont

About RSCI

redwood scientific technologies (rsci) is a pharmaceutical delivery company located in upland. ca. rsci develops, operates, and markets sublingual delivery products. we are the global leader in thin film oral delivery strips for lifestyle issues. our leading product tbx-free, is an aid to help with the addiction to nicotine. all rsci products are registered with the fda as over the counter and are listed in the national drug directory. rsci has a robust product pipeline that will be released over the next four years. our current products that are available range from a sleep aid to men’s sexual dysfunction aids. rsci's market strategy focuses on direct to consumers with a secondary emphasis on large wholesale distributors. in addition, rsci is in the developing stages of a complete product line for children. the first product to be released within that line will the version of children's ibuprofen in an easy to administer oral thin film strip. rsci is also expecting to have its first a